SCHEMBL6539362

SCHEMBL6539362

CCOC(=O)C[C@H](N)c1ccc(O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 3/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.47
CA12 O43570 4/20 0.47
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
CA7 P43166 4/20 0.47
CA9 Q16790 4/20 0.47
CA14 Q9ULX7 4/20 0.47
ESR1 P03372 3/20 0.47
ESR2 Q92731 2/20 0.47
F2 P00734 2/20 0.43
F10 P00742 2/20 0.43
TSHR P16473 2/20 0.41
MIF P14174 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 3/20 0.41
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6539360 1.00 KDM4E (0.48) KDM4EALDH1A1HTTKMT2ACA12
SCHEMBL1138963 0.88 KDM4E (0.49) KDM4EALDH1A1HTTKMT2AF2
SCHEMBL1138664 0.88 KDM4E (0.49) KDM4EALDH1A1HTTKMT2AF2
SCHEMBL6837445 0.88 KDM4E (0.49) KDM4EALDH1A1HTTKMT2AF2
SCHEMBL5720907 0.87 ESR1 (0.50) KDM4EALDH1A1HTTCA12CA1
SCHEMBL830224 0.85 ALDH1A1 (0.47) KDM4EALDH1A1HTTKMT2ACA12
SCHEMBL15545616 0.85 ALDH1A1 (0.47) KDM4EALDH1A1HTTKMT2ACA12
Hydrochloric Acid SCHEMBL7951117 0.85 KDM4E (0.50) KDM4EALDH1A1HTTKMT2AF2
SCHEMBL1294884 0.85 ALDH1A1 (0.47) KDM4EALDH1A1HTTKMT2ACA12
SCHEMBL5720861 0.85 ALDH1A1 (0.47) KDM4EALDH1A1HTTKMT2AF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB KDM4E 4771/4885ALDH1A1 578/4885HTT 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.